Patent Grant
8097590
This application is a National Stage application of PCT/FR2005/001164, filed May 10, 2005, which claims priority from French patent applications FR 0405069, filed May 11, 2004, and 0411279, filed Oct. 22, 2004. The entire contents of each of the aforementioned applications are incorporated herein by reference.
This invention relates to new alpha-MSH antagonist dipeptide conjugates and their use as a medicine or as a depigmenting agent.
Melanocortine receptors belong to the superfamily of seven transmembrane receptors coupled to protein G and they stimulate the AMPc signal transduction channel (Cone et al. Recent Prog. Horm. Res. 1996, 51, pages 287-317). The melanocortine system is involved in many physiological channels including pigmentation, inflammation, the erectile function, food behavior, energy homeostasis, weight homeostasis and the exocrine glands function. The endogenic agonist ligands for these melanocortine receptors are derived by post-translational modification of the transcript of the proopiomelanocortine gene, that during differential treatment causes generation of α, β and γ hormones stimulating melanocytes (MSH) and corticotrophine (ACTH). Subtypes of melanocortine receptors are activated by all endogenic melanocortine peptides, except for the melanocortine MC2 receptor that is only stimulated by corticotrophine. The family of melanocortine receptors also has two endogenic antagonists, namely agouti and protein related to agouti (AGRP) (Lu et al. Nature 1994, 371, pages 799-802, Ollmann et al., Science 1997, pages 135-138, Shulter et al., Genes Dev. 1997, 11, pages 593-602) that are the only known antagonists discovered at the moment existing in the natural state of these receptors coupled with protein G. These are polypeptides of 132 and 49 amino acid residues respectively. The most studied melanocortine receptor ligands are MC, receptor ligands of melanocortine of the skin that are involved in pigmentation and coloring of animal hair coat (Hruby et al. Ann. N.Y. Acad. Sci. 1993, 680, pages 51-63; Lerner et al. Nature 1961, pages 189, 176; Mountjoy et al. Science 1992, 257, pages 1248-1251).
Nonapepdide 153 N-6 (Jayawickreme et al., J. Biol. Chem. 1994, 269, pages 29846-29854) (H-Met-Pro-D-Phe-Arg-d-Trp-Phe-Lys-Pro-Val-NH2: Ki=11 nM) is a synthetic antagonist of the receptor MC1. However, this compound has a high molecular weight and therefore a very limited therapeutic or cosmetic activity. Its size makes it difficult to optimize and its bioavailability is limited. It is also expensive and difficult to prepare.
Tripeptide D-Trp-Arg-Leu-NH2 (Proc. Natl. Acad. Sci. (1995), 92, pages 2894-2898) also has an antagonist activity. However, it contains tryptophan that is an unstable amino acid and therefore can cause stability problems during storage.
Patent EP 1 174 437 describes di- or tripeptides comprising a naphthyl group and in particular a naphthylalanyl group. However, the presence of the naphthyl group increases the fabrication price of the product. Furthermore in some countries such as Japan, unnatural amino acid based peptides cannot be sold for cosmetic applications. Furthermore, no dipeptide activity is indicated.
Surprisingly, the inventors discovered that dipeptides conjugated at the C-terminal with carboxylic acids have an antagonist activity of the MSH alpha. These antagonists have a very low molecular weight and are therefore easy to optimize, they have good bioavailability and are very easy to prepare.
Therefore, this invention relates to a dipeptide conjugate with general formula I below:
A-AA2-AA1-NH2 I
in which
A represents the radical corresponding to a monocarboxylic acid with the following general formula II:
HOOC—R II
in which R represents
a linear or branched aliphatic radical in C1-C24, optionally substituted by a hydroxyl group, which can comprise one or more unsaturations, preferably between 1 and 6 unsaturations, and/or which can comprise a phenyl group,
or lipoic acid or the reduced form thereof, dihydrolipoic acid or N-lipoyllysine.
AA1 and AA2 represent identical or different amino acids chosen from the group consisting of Ala, Asn, Cys, Gln, Gly, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, Asp, Glu, Arg, H is, Lys, Orn, Dap, Dab, the corresponding homo-amino acids and the corresponding beta-amino acids,
in the form of enantiomers or diastereoisomers and mixtures thereof including racemic mixtures.
Amino acids in the dipeptide conjugate with formula (I) may have a D, L or DL configuration if it is not specified otherwise.
Thus, dipeptide conjugates with formula (I) may comprise one or more asymmetric carbon atoms. Therefore, they may exist in the form of enantiomers or diastereoisomers. The invention includes these enantiomers, diastereoisomers and mixtures thereof, including racemic mixtures.
Within the framework of this invention, the following abbreviations have the following meanings:
Note also that the dipeptide conjugates mentioned above according to this invention are obtained in the terminal form NH2 (in other words they present an amide function).
Dipeptide conjugates according to this invention are bonded to acid with formula II in the form of salts or esters. The conjugations according to this invention may be made by making the acid function of the amino acid react with the acid function of the formula II acid, or it is even possible to take advantage of the presence of a hydroxyl function on the formula II acid.
This invention relates to all these conjugations and non-functional conjugates. Conjugations may be physical or chemical.
Advantageously, at least one of the amino acids AA2 or AA1, and advantageously both of them, represent a basic amino acid, advantageously selected from the group consisting of Arg, H is, Dap, Dab, Orn or Lys, advantageously it will be Arg.
Advantageously, AA2 represents a basic amino acid advantageously selected from the group consisting of Arg, H is, Lys, Orn, Dap, Dab, advantageously it is Arg.
Advantageously, AA1 and/or AA2 do not represent Trp.
Advantageously, AA1 and/or AA2 do not represent Cys.
Advantageously, at least one of the amino acids AA1 or AA2 is selected from the group consisting of Ser and Pro.
Advantageously AA1 represents Pro.
Advantageously AA2 represents Ser.
Advantageously, the acid with formula (II) is a polyunsaturated fatty acid, in other words it comprises between 1 and 6 unsaturations. Even more advantageously, it is an omega-3 acid.
Among these omega-3 acids, there is particularly α-linolenic acid, cervonic acid, timnodonic acid and pinolenic acid. Cervonic, timnodonic and pinolenic acids are also known under the names 4,7,10,13,16,19-docosahexaenoic acid (DHA), 5,8,11,14,17-eicosapentaenoic acid (EPA) and 5,9,12-octodecatrienoic acid, respectively.
When A represents a monocarboxylic acid radical with general formula (II), it may advantageously be selected from among acetic acid, myristic acid, palmitic acid, hydroxydecenoic and decenoic acid, and particularly trans-10-hydroxy-Δ2-decenoic acid and trans-oxo-9-decene-2-oic acid.
Advantageously, acid with formula (II) is an acid selected from among lipoic acid (Lip) or its reduced form dihydrolipoic acid, N-lipoyllysine or phenylbutyric acid (Pbu).
Advantageously, A represents the radical corresponding to palmitic acid (Palm).
The dipeptide conjugates of the invention include the dipeptide conjugates selected from among the group consisting of:
a) A-Arg-His-NH2,
b) A-Arg-Arg-NH2,
c) A-Arg-Pro-NH2,
d) A-Arg-Lys-NH2,
e) A-Ser-Pro-NH2,
f) A-DPhe-Arg-NH2,
in which the definition of A is as given above.
In particular, the dipeptide conjugates in the invention may be selected from among the group consisting of
39) Palm-Arg-His-NH2,
41) Palm-Arg-Arg-NH2,
49) Palm-Arg-Pro-NH2,
50) Palm-Arg-Lys-NH2,
125) Palm-Ser-Pro-NH2,
269) Palm-DPhe-Arg-NH2,
362) Pbu-DPhe-Arg-NH2,
363) Lip-DPhe-Arg-NH2
Dipeptide conjugates according to this invention may be obtained either advantageously by classical chemical synthesis, or by enzymatic synthesis using any processes known to those skilled in the art.
This invention also relates to a cosmetic, dermatological or pharmaceutical composition or a food supplement comprising a dipeptide conjugate according to this invention and possibly a cosmetically or pharmaceutically acceptable excipient.
Dipeptide conjugates can be administered for their cosmetic or pharmaceutical use by topical route. They can also be used orally in food supplements, in other words in the nutraceutical domain.
Dipeptide conjugates according to the invention are preferably administered topically.
The cosmetic, pharmaceutical or dermatological composition according to this invention intended for topical administration may be presented in forms that are normally known for this type of administration, in other words particularly lotions, foams, gels, dispersions, sprays, serums, masks, body milk, pomades, solutions, emulsions, gels, or creams for example with excipients particularly for skin penetration in order to improve the properties and accessibility of the active ingredient. These compositions usually also contain the dipeptide conjugate according to this invention and usually also a physiologically acceptable medium, usually based on water or solvent, for example alcohols, ethers or glycols. They can also contain surface active agents, preservatives, stabilizers, emulsifiers, thickeners, other active constituents leading to a complementary or possibly synergic effect, trace elements, essential oils, perfumes, coloring agents, collagen, chemical or mineral filters, moisturizers or thermal water.
In the composition according to this invention, the dipeptide conjugate according to the invention may be present at a concentration of between 10−8 M and 10−3 M, advantageously between 10−7 M and 10−5 M.
This invention also relates to a dipeptide conjugate according to this invention or a pharmaceutical composition according to this invention for its use as a medicine, advantageously designed to prevent, improve or treat immunitary abnormalities, immunodeficiency, to regulate the body weight by controlling the appetite, to treat disorders of the central nervous system, to regulate satiety, to treat anorexia or some skin cancers.
This invention also relates to the use of a cosmetic composition according to this invention as a depigmenting agent to lighten or whiten the epidermis, to eliminate skin spots, particularly age spots or freckles, or to prevent pigmentation of the epidermis.
Finally, this invention relates to a cosmetic treatment process to lighten, depigment or whiten the epidermis, to eliminate skin spots and particularly age spots or freckles, or prevent pigmentation of the epidermis including application of a cosmetic composition according to this invention to the skin.
The following examples are given for non-limitative guidance.
A bank of acylated dipeptides with 361 members was synthesized using SynPhase™ Lanterns and a “split and pool” strategy for color marking as described in the article by Feliu et al. (J. Comb. Chem., 2003, 5, pages 256-361).
Thus, these 361 compounds were synthesized on series D SynPhase™ Lanterns with Rink amide PS resin using the standard Fmoc (9-fluorenyl-methoxycarbonyl) synthesis strategy in the solid phase using a Multipin 96 arrangement format. Component blocks AA1 and AA2 were selected from a chemical assembly of 19 D and L amino acids including several types of lateral chains (alkyl, aromatic, acid, voluminous, basic) to produce 19×19=361 combinations.
The following chemical products were used:
Amino acids protected at the N-terminal end by an α-Fmoc, Fmoc-Ala-OH, Fmoc-D-Ala-OH, Fmoc-Arg(Pbf)-OH, Fmoc-D-Arg-(Pbf)-OH, Fmoc-His(Trt)-OH, Fmoc-D-His(Trt)-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, Fmoc-D-Phe-OH, Fmoc-Trp(Boc)-OH, Fmoc-D-Trp(Boc)-OH, Fmoc-Met-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Leu-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Gly-OH, Fmoc-Pro-OH, or Fmoc-Asn(trt)-OH group, were purchased from SENN chemicals and Advanced Chemtech.
The coupling agent, HBTU (hexafluorophosphate of 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyl-uronium), was purchased from SENN chemicals.
N,N-dimethylformamide (DMF), dichloromethane, methanol, acetonitrile, ethyl ether, trifluoroacetic acid (TFA), piperidine were purchased from Riedel de Haen, Carlo Erba or Acros organics and used without purification.
N,N-diisopropylethylamine (DIEA), triisopropyl-silane, palmitic acid were purchased from Aldrich or Avocado. All reagents and chemical products were of analytic quality and they were used without any other purification.
D series Synphase Polystyrene Rink amide Lanterns were supplied by Mimotopes, Pty.
The standard procedure for manufacturing these dipeptides includes the following steps:
1—Fmoc Standard Deprotection Protocol
Fmoc deprotection steps were done by immersing lanterns immobilized on a support of 96 rods in a mix of dimethylsulfoxide (DMF)/piperidine (80/20, v/v) for 30 minutes. Rectangular polypropylene receptacles of the same size as a standard plate with 96 wells were used. The excess deprotection solution was simply eliminated by stirring the rod support vigorously.
2—Standard Washing Protocol
After the coupling or deprotection step, washing steps were carried out by dipping the lanterns arranged in a Multipin format into polypropylene receptacles containing DMF (3×5 min), methanol (2×5 min) and dichloromethane (DCM) (1×5 min), all in sequence. The lanterns were dried in air for 5 minutes under a vapor hood after the last washing with DCM.
3—Standard Coupling Protocol
0.4 M solutions of each Fmoc amino acid, HBTU and DIEA were prepared in DMF and were kept at 4° C. throughout the synthesis. 200 μl of amino acid solution were distributed in plates with 96 deep wells. 200 μl of DIEA solution and 200 μl of HBTU solution were then added and finally, the support of the rods supporting the lanterns was adapted to the deep wells plate for 2 hours.
4—Cleavage
500 μl of TFA/water/triisopropylsilane (95/2.5/2.5, v/v/v) solution was distributed in individual polypropylene tubes arranged in Micronic plates with 96 wells. Cleavage was done for 3 hours. The cleavage cocktail was concentrated directly from plates using a Jouan RC1010 vacuum centrifuge. Compounds were precipitated with dry diethyl ether, and were centrifuged and settled one by one. Precipitation, centrifuging and settlement operations were repeated twice. 500 μl of acetonitrile/water (50/50, v/v) containing 0.1% of TFA were distributed in each tube to solubilize the samples. The samples were then frozen at −80° C. and freeze dried. This operation was repeated twice to completely eliminate the triisopropylsilane purification group.
5—Preparation and Analysis of Samples
Complete banks and simple re-synthesized peptides were analyzed by CLHP in inverse phase and CL/SM. 500 μl of acetonitrile/water (50/50, v/v) containing 0.1% of TFA were distributed on the freeze-dried compounds. 10 μl of each tube was sampled for analysis of CLHP and CL/SM ESI+.
The CLHP analyses were carried out on a CLHP Waters Alliance 2690 system and a Waters 996 photodiode strip detector and a 50×4.6 mm Merck Chromolith Speed ROD C18 column. A flow rate of 5 ml/min and a gradient from 100% of B to 100% of C was used over 3 minutes (Eluant B, water/0.1% of TFA; Eluant C, acetronitrile/0.1% of TFA). Estimates of the purity are based on the percent of the area of peaks detected at 214 nm.
The CL/SM system was composed of a Waters Alliance 2690 CLHP coupled to a Micromass Platform II spectrometer (ionization by electronebulization mode; ESI+). All analyses were done using a 2.1×30 mm Waters Symmetry C18 column, 3.5 μm. A 600 μl/min flow rate and a gradient from 100% of B to 100% of C over 3 minutes were used (Eluant B, water/0.1% of TFA; Eluant C, acetonitrile/0.1% of TFA).
Mass spectra by positive ionic electronebulization were acquired at a solvent flow rate of 100 ml/min. Nitrogen was used both for the nebulizing gas and for the drying gas. Data were acquired in read mode m/z 400 to 1400 at intervals of 0.1−s; 10 readings were added to produce the final spectrum.
The molecular weights of all compounds were calculated using mono-isotopic masses (C=12.000, H=1.007, N=14.003, O=15.994, S=31.972).
Table 1 below contains the analysis results.
Except for 35 members of the bank (shown in grey), all compounds were detected by a CL/SM ES+ analysis. The average purity determined based on the percent of the area of the expected peak detected at 214 nm on the chromatogram is greater than 83%.
Experiments on inhibition of AMPc production were carried out on the M4Be human cell line with a concentration of 5×10−8 M of α-MSH. Five Palm-dipeptides according to this invention were introduced at different concentrations and each measurement was made in triplicate. Two or three series of experiments were made.
The tests were made as follows:
The M4Be human cell line (Jacubovich et al. Cancer Immunol. Immunother. 1979, 7, 59-64), a melanocytes cell line capable of producing melanines, was used in this study to determine the values of CI50.
The cells were maintained in the Dulbecco modified Eagle medium with 10% of foetal calf serum (FCS), 1 mM of glutamine, 100 U/ml of penicillin and 10−4 g/ml of streptomycine.
All cell lines were maintained at 37° C. in an atmosphere with 5% of CO2 and cell culture media were renewed every two days. The cells were applied in contact with a plate with 96 wells (Nunc, Roskilde) 24 hours before contact of dipeptides according to the invention.
AMPc was measured as follows:
Cells applied in contact the day before with 8×104 cells per well were put in the presence of one of the five dipeptide conjugates according to the invention at various concentrations for 10 minutes at 37° C. with 5×10−8 M of α-MSH. After this time, the lysis of the cells was made and the AMPc content was measured using a connection test box by competition (RPN225, Amersham Pharmacia Biotech). Each independent experiment was carried out at least twice in triplicate.
The peptidic activity was determined with reference to the AMPc content synthesized by untreated cells and the production of AMPc induced by α-MSH alone. The curves were adjusted and the values of CI50 were determined with non-linear regression in the GraphPad Prism (GraphPad software, San Diego, Calif., United States).
Table 2 below contains the results.
Thus, unexpectedly, the tested Palm-dipeptides appeared to be antagonists of the human MC1 receptor of melanocortine using M4Be melanoma cell lines. These dipeptide conjugates have a CI50 within a micromolar range. These dipeptides are the first example of short synthesis antagonist compounds binding to the MC1 receptor and they open up the field for small molecule non-peptidic antagonists of α-MSH.
In particular, these compounds comprise an arginine residue in position AA2. Interestingly, compound 125 (Palm-Ser-Pro-NH2) does not have any basic residue in its sequence, and has a value of CI50 equal to 17 μM. This result showed that the bond to the MC1 receptor does not necessarily require a positively charged radical.
With only two amino acid residues, these palmitoyled compounds can be considered as being leader compounds useful for design of non-peptide antagonists of α-MSH.
| Number | Date | Country | Kind |
|---|---|---|---|
| 04 05069 | May 2004 | FR | national |
| 04 11279 | Oct 2004 | FR | national |
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/FR2005/001164 | 5/10/2005 | WO | 00 | 5/23/2007 |
| Publishing Document | Publishing Date | Country | Kind |
|---|---|---|---|
| WO2005/115174 | 12/8/2005 | WO | A |
| Number | Name | Date | Kind |
|---|---|---|---|
| 5674839 | Hruby et al. | Oct 1997 | A |
| 5714576 | Hruby et al. | Feb 1998 | A |
| 5719126 | Nordlund et al. | Feb 1998 | A |
| 5786332 | Girten et al. | Jul 1998 | A |
| 5830994 | D'Hinterland et al. | Nov 1998 | A |
| 6054556 | Hruby et al. | Apr 2000 | A |
| 6228840 | Wei et al. | May 2001 | B1 |
| 6245342 | Golz-Berner et al. | Jun 2001 | B1 |
| 6337315 | Mahe et al. | Jan 2002 | B1 |
| 6372717 | Greff | Apr 2002 | B1 |
| 6579848 | Hearing, Jr. | Jun 2003 | B1 |
| 20030194445 | Kuhner et al. | Oct 2003 | A1 |
| 20040010010 | Ebetino et al. | Jan 2004 | A1 |
| 20050187164 | Pinel | Aug 2005 | A1 |
| Number | Date | Country |
|---|---|---|
| 0 389 950 | Oct 1990 | EP |
| 0 669 938 | Sep 1995 | EP |
| 0 949 902 | Oct 1999 | EP |
| 0 972 522 | Jan 2000 | EP |
| 1 174 437 | Jan 2002 | EP |
| 1327363 | May 1962 | FR |
| 2805744 | Sep 2001 | FR |
| 2 810 323 | Dec 2001 | FR |
| 1 000 897 | Aug 1965 | GB |
| WO 9508564 | Mar 1995 | WO |
| WO 9807744 | Feb 1998 | WO |
| WO 9825584 | Jun 1998 | WO |
| WO 0164178 | Sep 2001 | WO |
| WO 0198362 | Dec 2001 | WO |
| WO 02085925 | Oct 2002 | WO |
| WO 03064458 | Aug 2003 | WO |
| WO 03095474 | Nov 2003 | WO |
| WO 2004099237 | Nov 2004 | WO |
| WO 2004110341 | Dec 2004 | WO |
| WO 2005116068 | Dec 2005 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 20070231284 A1 | Oct 2007 | US |
